EGFR and cancer: Interestingly, our results demonstrated that when EGFR‐mutated cancer cells were exposed to CM from PCs, the effect on the sensitivity of first‐/second‐generation TKI drugs was not as pronounced as the effect on the third‐generation TKI drugs (Figure S2C, Supporting Information).